Differentiating oncocytic carcinoma from oncocytic adenoma: a comprehensive evaluation of preoperative characteristics and diagnostic approaches in a retrospective cohort study

鉴别嗜酸性癌与嗜酸性腺瘤:回顾性队列研究中术前特征和诊断方法的全面评估

阅读:3

Abstract

PURPOSE: Oncocytic carcinoma (OCA) has been reclassified from follicular thyroid carcinoma due to its unique features. Its rarity has resulted in limited studies on differentiating OCA from oncocytic adenoma (OA). This study aimed to compare the clinicopathologic and preoperative features of OCA and OA and evaluate the effectiveness of ultrasonography and cytology. METHODS: We conducted a retrospective study involving 83 patients (23 with OCA and 60 with OA) who underwent thyroid surgery between 2011 and 2024. We reviewed clinical, ultrasonographic, cytologic, and histopathologic data to assess diagnostic performance. RESULTS: OCA cases had larger tumors than OA in both sonographic (4.2 ± 1.7 cm vs. 2.7 ± 1.4 cm, P < 0.001) and pathologic measurements (3.8 ± 1.7 cm vs. 2.3 ± 1.4 cm, P < 0.001). K-TIRADS (the Korean Thyroid Imaging Reporting and Data System) did not effectively distinguish OCA from OA; however, ACR TI-RADS (the American College of Radiology Thyroid Imaging Reporting and Data System) categorized more OCA cases into higher-risk groups (17.4% vs. 1.7%, P = 0.016). Trabecular formation and intranodular vascularity were more frequent in OCA (17.4% vs. 1.7%, P = 0.019; 65.2% vs. 33.3%, P = 0.049). Cytologically, 87% of OCAs were classified as follicular neoplasms compared to 20% of OAs. CONCLUSION: Predicting malignancy in oncocytic neoplasms is challenging. Larger tumor size, higher ACR TI-RADS scores, and trabecular formation are potential indicators for OCA. Cytologic subcategorization within Bethesda IV suggests follicular neoplasms carry a higher malignancy risk than oncocytic neoplasms. Multicenter studies are needed to validate these findings.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。